Main Research Findings

1) Treatment with L-carnitine was shown to protect against several factors of cardiovascular disease while regulating metabolic characteristics related to heart failure.

2) L-carnitine was found to reduce hypoxic damage and elicit neuroprotective effects by regulating increased acetylcholine levels in the cerebrum.

 

Selected Data

1) The research team of Wang et al completed a comprehensive narrative review that examines the role of L-carnitine in the prevention and treatment of cardiovascular disease, with particular emphasis on ventricular dysfunction, ischemia-reperfusion injury, cardiac arrhythmias, and toxic myocardial injury. Rather than presenting findings from a single experimental study, the researchers synthesized evidence from previously published clinical trials, animal studies, mechanistic investigations, and meta-analyses to provide an updated overview of L-carnitine’s physiological functions and therapeutic potential in cardiac disease. The review was designed to integrate biochemical, pharmacological, and clinical evidence to explain how L-carnitine influences myocardial metabolism and cardiovascular outcomes [1].
The research team first established the physiological foundation of L-carnitine by reviewing its pharmacokinetics, intermediary metabolism, and mechanisms of action within cardiac tissue. Particular attention was devoted to the mitochondrial transport of long-chain fatty acids through the carnitine shuttle system involving carnitine palmitoyltransferase I (CPT-I), carnitine-acylcarnitine translocase, and carnitine palmitoyltransferase II. The review described how these transport systems regulate fatty acid oxidation, ATP production, and mitochondrial energy metabolism within cardiomyocytes. In addition, the researchers summarized the endogenous synthesis of L-carnitine, dietary sources, tissue distribution, and the importance of the organic cation transporter OCTN2 in maintaining adequate intracellular carnitine concentrations. Genetic disorders affecting OCTN2 function and systemic primary carnitine deficiency were also reviewed because of their direct relationship with cardiomyopathy and cardiac dysfunction.
The review next examined studies describing the metabolic consequences of carnitine deficiency and excessive acylcarnitine accumulation within cardiac muscle. Experimental investigations involving isolated cardiomyocytes, animal models, and biochemical analyses were summarized to explain how impaired fatty acid transport disrupts mitochondrial oxidative phosphorylation, pyruvate dehydrogenase activity, ATP synthesis, calcium homeostasis, membrane stability, and myocardial contractility. The researchers incorporated mechanistic evidence describing oxidative stress, mitochondrial dysfunction, alterations in sodium-potassium ATPase activity, calcium overload, endothelial dysfunction, and reactive oxygen species generation to explain how metabolic disturbances contribute to cardiac pathology. Diagrams illustrating mitochondrial fatty acid transport and the toxic effects of acylcarnitine accumulation were included to support these mechanistic descriptions [1].

 

Figure 1: A schematic representing carnitine mediated mitochondrial transport of long chain fatty acids and fatty acid oxidation, resulting in the transport of acetylcarnitine out of the cell
The clinical evidence reviewed encompassed a wide range of patient populations, including individuals with chronic heart failure, myocardial infarction, ventricular dysfunction, ischemia-reperfusion injury, arrhythmias, toxic myocardial injury, pediatric cardiomyopathy, and metabolic disorders associated with carnitine deficiency. The research team summarized randomized clinical trials, multicenter studies, observational investigations, and meta-analyses evaluating oral and intravenous L-carnitine supplementation. Reported interventions varied considerably in dosage, ranging from approximately 2 g/day orally to 6–9 g/day intravenously, with treatment durations extending from several days following myocardial infarction to one year of long-term follow-up. Outcomes assessed across these studies included ventricular function, infarct size, mortality, exercise capacity, cardiac remodeling, biomarkers such as BNP and NT-proBNP, oxidative stress, inflammatory mediators, electrocardiographic findings, and patient survival. Animal studies involving rodents, guinea pigs, swine, and canine models were also incorporated to evaluate molecular mechanisms that could not be directly examined in human subjects [1].
Rather than conducting statistical pooling or formal meta-analysis, the research team organized the available literature into major disease categories. Separate sections summarized evidence regarding ventricular dysfunction, ischemia-reperfusion injury, cardiac arrhythmias, and toxic myocardial injury, allowing comparisons of proposed mechanisms and therapeutic outcomes across different cardiovascular disorders. Throughout the review, evidence from basic science experiments was integrated with clinical findings to illustrate how improvements in mitochondrial metabolism, fatty acid oxidation, endothelial function, antioxidant defenses, calcium regulation, and inflammatory signaling may collectively explain the cardioprotective effects observed following L-carnitine supplementation. This broad evidence synthesis enabled the research team to evaluate both the biological plausibility and the clinical relevance of L-carnitine as a therapeutic strategy for cardiovascular disease [1].
2) The research team of Shen et al conducted a comprehensive narrative review to examine the potential role of L-carnitine in preventing or reducing neuromuscular fatigue associated with KAATSU training, also known as blood flow restriction (BFR) training. Rather than performing new laboratory experiments, the review integrates evidence from previous human studies, animal investigations, mechanistic laboratory research, and sports physiology literature to explain the biological pathways through which KAATSU training induces fatigue and how L-carnitine supplementation may counteract these effects. The review was designed to bridge multiple fields, including exercise physiology, neuromuscular biology, mitochondrial metabolism, nutrition, and neuroscience, to provide a mechanistic framework linking blood flow restriction exercise, hypoxia, neurotransmitter function, and nutritional intervention [2].
The review begins by examining the physiological characteristics of KAATSU training. The research team summarized literature demonstrating that restricting venous blood flow during low-intensity resistance exercise produces muscle hypertrophy and strength gains comparable to conventional high-intensity resistance training. However, because vascular occlusion reduces oxygen availability within working muscles, the review evaluates evidence suggesting that this temporary hypoxic environment contributes to metabolic stress and neuromuscular fatigue. Studies investigating serum lactate accumulation, oxygen delivery, vascular restriction pressures, electromyographic activity, and fatigue development were synthesized to describe how varying degrees of hypoxia influence both peripheral and central mechanisms of fatigue. Previous investigations involving athletes and controlled exercise models were reviewed to establish relationships among vascular restriction pressure, tissue oxygen deprivation, anaerobic metabolism, and reductions in muscular performance.
The researchers then reviewed studies examining the physiological consequences of hypoxia on skeletal muscle metabolism. Experimental evidence describing pyruvate metabolism, lactate production, mitochondrial dysfunction, ATP depletion, oxidative stress, hydrogen ion accumulation, and metabolic acidosis was incorporated to explain why blood flow restriction increases fatigue during exercise. The review summarizes findings from biochemical studies describing alterations in glycolysis, pyruvate dehydrogenase activity, acetyl-CoA formation, and tricarboxylic acid (TCA) cycle activity under hypoxic conditions. Diagrams illustrating these metabolic pathways are used throughout the article to demonstrate how reduced oxygen availability disrupts energy production and promotes neuromuscular dysfunction [2].
A substantial portion of the review focuses on L-carnitine biology. The research team synthesized studies describing endogenous L-carnitine synthesis, dietary sources, tissue distribution, and its well-established role in mitochondrial fatty acid transport and oxidative metabolism. Human supplementation studies and animal experiments were examined to evaluate how oral L-carnitine increases circulating carnitine concentrations, enhances oxygen utilization, improves mitochondrial respiration, stimulates ATP production, and reduces oxidative stress. Research involving respiratory muscle function, skeletal muscle remodeling, exercise recovery, and attenuation of exercise-induced muscle soreness was also incorporated to illustrate the broad physiological effects of L-carnitine supplementation [2].

 

Figure 2: A schematic representing the mechanism through which L-carnitine mediates the adaptation to hypoxia-induced neuromuscular fatigue in relation to KAATSU training.
The review further examines literature addressing neurotransmitter metabolism, particularly acetylcholine synthesis. The researchers compiled evidence showing that acetyl-L-carnitine crosses the blood-brain barrier and serves as an alternative source of acetyl-CoA for acetylcholine production. Studies evaluating cholinergic neuron function, neurotransmitter biosynthesis, cerebral metabolism, and neuromuscular junction physiology were summarized to support the hypothesis that L-carnitine may reduce neuromuscular fatigue by preserving acetylcholine availability during exercise. Previous investigations examining neurotransmitter depletion, presynaptic acetylcholine release, and neuromuscular transmission failure were integrated into this mechanistic model.
Rather than statistically combining data through a formal meta-analysis, the researchers organized evidence into thematic sections addressing hypoxia, muscle metabolism, mitochondrial energy production, neurotransmitter synthesis, and fatigue mechanisms. Human clinical studies, animal experiments, biochemical analyses, and physiological models were collectively interpreted to develop a comprehensive mechanistic explanation for how L-carnitine supplementation may attenuate KAATSU training-induced neuromuscular fatigue. The review concludes by identifying important gaps in the literature and emphasizing the need for future translational studies directly examining L-carnitine supplementation during blood flow restriction exercise [2].

 

Discussion
1) The review performed by the research team of Wang et al concluded that substantial experimental and clinical evidence supports a cardioprotective role for L-carnitine across multiple forms of cardiovascular disease. The primary mechanism underlying these benefits involves restoration of mitochondrial fatty acid oxidation, improved ATP generation, reduction of oxidative stress, stabilization of cellular membranes, and preservation of myocardial energy metabolism. By facilitating the transport of long-chain fatty acids into mitochondria, L-carnitine improves metabolic efficiency while limiting the accumulation of toxic acylcarnitine intermediates that contribute to myocardial injury, calcium overload, membrane disruption, and impaired cardiac contractility. These biochemical effects collectively reduce oxidative damage, inflammation, endothelial dysfunction, and cardiomyocyte death [1].
Among patients with ventricular dysfunction, several clinical studies demonstrated meaningful improvements following L-carnitine supplementation. The review highlighted the multicenter CEDIM trial, in which patients receiving intravenous L-carnitine after acute myocardial infarction experienced improved left ventricular function, smaller infarct size, reduced ventricular enlargement, fewer cases of heart failure, and lower mortality compared with placebo-treated individuals. Additional studies reported improvements in exercise tolerance, electrocardiographic parameters, cardiopulmonary performance, and overall cardiac function following several months of oral supplementation. Pediatric patients with cardiomyopathy also showed improved survival and clinical outcomes when treated with L-carnitine. Furthermore, meta-analyses demonstrated substantial reductions in circulating BNP and NT-proBNP concentrations, biomarkers that reflect ventricular stress and heart failure severity.
The review also presented considerable evidence supporting the use of L-carnitine in ischemia-reperfusion injury. During ischemia, myocardial carnitine concentrations decline while toxic acylcarnitines accumulate, leading to impaired β-oxidation, ATP depletion, oxidative stress, calcium dysregulation, and mitochondrial dysfunction. Experimental studies demonstrated that exogenous L-carnitine restored myocardial energy metabolism, preserved mitochondrial adenine nucleotide concentrations, enhanced glucose utilization and glycogen synthesis, maintained ventricular pressure and cardiac output, and improved cardiomyocyte survival following ischemic injury. The research team concluded that L-carnitine reduces metabolic disturbances that occur during reperfusion and limits irreversible myocardial damage through improved mitochondrial function and antioxidant activity [1].
Evidence regarding cardiac arrhythmias further supported the protective role of L-carnitine. The review described how excessive acylcarnitine accumulation alters membrane excitability, calcium handling, sodium-potassium ATPase activity, gap junction communication, and electrical impulse propagation, thereby increasing susceptibility to arrhythmias. Experimental animal studies demonstrated that L-carnitine supplementation prevented conduction abnormalities, reduced abnormal electrical activity, inhibited atrioventricular reentrant tachycardia, and stabilized myocardial electrophysiology. These effects were attributed to improved mitochondrial oxidative phosphorylation, normalization of membrane transport systems, and suppression of mechanical and electrical disturbances within cardiac tissue [1].
The researchers also reviewed evidence supporting L-carnitine as a protective agent against toxic myocardial injury. Studies involving aluminum phosphide poisoning, isoproterenol-induced cardiac stress, pivalic acid-associated carnitine depletion, doxorubicin cardiotoxicity, and adriamycin exposure consistently demonstrated that L-carnitine reduced oxidative stress, inflammation, apoptosis, myocardial fibrosis, and ventricular dysfunction. Supplementation restored mitochondrial energy production, improved cardiac histology, maintained blood pressure, preserved immune function, and prevented deterioration of cardiac performance without reducing the therapeutic efficacy of anticancer agents such as doxorubicin. These findings suggest that L-carnitine may serve as an important adjunctive therapy in conditions characterized by drug-induced myocardial toxicity.
Overall, the research team concluded that L-carnitine possesses broad therapeutic potential across numerous cardiovascular disorders by improving myocardial energy metabolism, limiting oxidative injury, suppressing inflammation, preserving mitochondrial function, and reducing ventricular dysfunction, ischemic damage, arrhythmias, and toxic myocardial injury. Although the evidence reviewed was largely favorable, the researchers emphasized that additional large multicenter clinical trials are needed to establish optimal dosing strategies, evaluate long-term outcomes, and determine the effectiveness of L-carnitine supplementation before and after cardiovascular surgery [1].
2) The evidence summarized throughout the review completed by the research team of Shen et al indicates that KAATSU training produces significant improvements in muscle hypertrophy and strength despite using relatively low exercise intensities. However, the restriction of venous blood flow creates a hypoxic environment within exercising muscles, leading to increased reliance on anaerobic metabolism. The reviewed studies consistently demonstrate that hypoxia results in elevated lactate production, reduced oxygen delivery, impaired mitochondrial function, decreased ATP synthesis, accumulation of metabolic byproducts, and increased oxidative stress. Together, these metabolic disturbances contribute to the development of both peripheral and central components of neuromuscular fatigue. The research team concluded that while KAATSU training is highly effective for muscle adaptation, its beneficial effects are accompanied by physiological mechanisms that increase fatigue susceptibility [2].
The review highlights evidence demonstrating that neuromuscular fatigue develops through multiple interacting pathways. Peripheral fatigue results primarily from metabolic disturbances within skeletal muscle, including impaired excitation-contraction coupling, reduced force generation, and altered neuromuscular junction function. Central fatigue involves reduced neural drive originating within the central nervous system and increased perception of effort during prolonged exercise. Studies reviewed by the researchers suggest that moderate hypoxia induced during KAATSU training activates both peripheral and central fatigue mechanisms simultaneously. Investigations using varying vascular occlusion pressures reported greater neuromuscular fatigue with increasing blood flow restriction, indicating that fatigue severity is closely related to the degree of hypoxic stress experienced during exercise.
The strongest body of evidence presented in the review supports a protective role for L-carnitine supplementation. Human and animal studies consistently demonstrated that oral L-carnitine increases circulating carnitine concentrations, improves oxygen utilization, enhances mitochondrial respiration, and supports fatty acid oxidation. These metabolic improvements increase ATP production while simultaneously reducing lactate accumulation, oxidative stress, and metabolic acidosis. The research team described several studies showing that L-carnitine supplementation improves exercise recovery, decreases muscle soreness, preserves mitochondrial function, and attenuates tissue hypoxia following strenuous exercise. By improving cellular energy metabolism, L-carnitine appears capable of reducing many of the metabolic abnormalities responsible for fatigue development during blood flow restriction exercise [2].
The review also emphasizes the neuroprotective properties of acetyl-L-carnitine. Evidence from animal studies indicates that acetyl-L-carnitine crosses the blood-brain barrier and supplies acetyl groups that increase acetyl-CoA availability within neurons. Increased acetyl-CoA enhances acetylcholine synthesis, thereby improving cholinergic neurotransmission. Because reductions in acetylcholine release contribute directly to neuromuscular junction failure and peripheral fatigue, the researchers propose that increased acetylcholine availability represents an additional mechanism by which L-carnitine reduces neuromuscular fatigue. The review integrates studies demonstrating improved cholinergic neuron viability, enhanced neurotransmitter synthesis, and greater neuromuscular transmission following acetyl-L-carnitine supplementation.
Collectively, the reviewed evidence supports the hypothesis that L-carnitine acts through several complementary biological pathways. It increases mitochondrial oxygen consumption, restores ATP production through enhanced fatty acid oxidation, reduces lactate accumulation by maintaining pyruvate dehydrogenase activity, limits oxidative damage, improves metabolic homeostasis, and increases acetylcholine synthesis. These physiological adaptations may collectively reduce both hypoxia-induced metabolic dysfunction and neurotransmitter-related fatigue during KAATSU exercise. Figures presented within the review illustrate how L-carnitine influences mitochondrial metabolism, acetylcholine production, and neuromuscular function through interconnected biochemical pathways [2].

 

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

 

Citations

[1] Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci. 2018;194:88-97. doi:10.1016/j.lfs.2017.12.015

[2] Shen L, Li J, Chen Y, Lu Z, Lyu W. L-carnitine’s role in KAATSU training- induced neuromuscular fatigue. Biomed Pharmacother. 2020;125:109899. doi:10.1016/j.biopha.2020.109899

 

L-Carnitine is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.